The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression.
European journal of cancer (Oxford, England : 1990)
View this publicationMember, Steering-Committee Member
Medical Faculty, University of Bonn University Hospital of Bonn Sigmund-Freud-Strasse 25 53127 Bonn
Michael Hölzel has long-standing research expertise in the field of tumor biology and functional genomics with a particular focus on neural crest derived tumors such as melanoma. Currently his group investigates how the im-mune system crosstalks with the tumor cells in response to danger and proinflammatory signals released by therapy- induced tumor tissue injury. A central hypothesis is that this reciprocal communication drives therapy relapse due to rewiring of survival and differentiation pathways in tumor cells. This knowledge is critically needed for the rational combination of immunotherapies and targeted signal transduction inhibitors in the clinic.
European journal of cancer (Oxford, England : 1990)
View this publicationEuropean journal of immunology
View this publicationNature reviews. Urology
View this publication